Industries > Pharma > Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report 2021-2031

Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report 2021-2031

Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs plus Leading Anti-Idiopathic Pulmonary Fibrosis Drugs companies analysis

PAGES: 171
PRODUCT CODE: PHA0788
SUBMARKET: Therapeutic Drugs

DOWNLOAD FREE SAMPLE
Clear
WOOCS 2.2.1
SKU: PHA0788 Categories: , Tag:

The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of xyz% in the first half of the forecast period. In 2018, the anti-fibrotics held the largest market share (xyz%) followed by the tyrosine kinase inhibitors.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 170+ page report you will receive over 70 tables and figures– all unavailable elsewhere.

The 171-page report provides clear detailed insight into the global anti-idiopathic pulmonary fibrosis drugs market. Discover the key drivers and challenges affecting the market.

To access the data contained in this document please email contactus@visiongain.com

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2021

• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action:
• Antifibrotics
• Tyrosine Kinase Inhibitors
• Anti-inflammatory Drugs
• Immunosuppressants
• Other MoA

This report will have a series of economic case scenarios as to the impact of COVID-19 on the IPF Global market.

• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs:
• Innovator Drugs
• Off-label Drugs

• This report provides individual revenue forecasts to 2029 for these national markets:
• US
• Japan
• EU5: Germany, France, the UK, Italy, Spain
• Rest of World

• This report provides individual revenue forecasts to 2029 for these marketed drugs:
• Esbriet
• Ofev

• Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses:
• Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets
• Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity
• Epidemiology of Idiopathic Pulmonary Fibrosis by gender
• Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis
• Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS)
• A SWOT Analysis of the anti-idiopathic pulmonary fibrosis drugs market

• Our study discusses the marketed anti-idiopathic pulmonary fibrosis drugs and pipeline anti-idiopathic pulmonary fibrosis drugs from these companies:
• Actelion
• Afferent Pharmaceuticals
• Asahi Kasei Pharma
• Bellerophon Therapeutics
• Biogen
• Boehringer Ingelheim
• FibroGen
• Galapagos
• Galecto Biotech
• Genentech
• Global Blood Therapeutics
• GSK
• Kadmon Pharmaceuticals
• LTT Bio-Pharma
• MediciNova
• Merck
• Moerae
• Pacific Therapeutics
• Promedior
• ProMetic Life Sciences
• Roche
• Sanofi
• Teva
• Zai Lab

Visiongain’s study is intended for anyone requiring commercial analyses for the global Anti-Idiopathic Pulmonary Fibrosis Drugs Market. You find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report 2021-2031: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories